

FMHL/SE/BM/OCT'19

October 30, 2019

The General Manager
Department of Corporate Services
BSE Limited
PhirozeJeejeebhoy Towers,
Dalal Street, Mumbai – 400 001
Scrip Code: 523696

Sub: Outcome of the Board Meeting

Dear Sir,

Pursuant to the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosures Requirement) Regulation, 2015, this is to inform you that the Board of Directors of the Company at its meeting held today i.e. October 30, 2019, *inter-alia*, considered and approved un-audited standalone and consolidated financial results of the Company for the quarter and period ended on September 30, 2019 along with limited review report thereon;

Please find enclosed Un-audited standalone and consolidated financial results along with limited review report for quarter and period ended on September 30, 2019, a 'Statement of Assets & Liabilities' and a statement of cash flow for the half year ended September 30, 2019 and a copy of the press release being issued in this regard.

The Board Meeting commenced at 10:30 A.M. and concluded at 05:45 P.M.

This is for your information and records please.

Yours faithfully
For Fortis Malar Hospitals Limited

Digitally signed
by Shashank
Porwal
Date: 2019.10.30
17:42:19 +05'30'

Shashank Porwal
Company Secretary

B S R & Co. LLP

Chartered Accountants

KRM Tower, 1st & 2nd Floor,
No 1, Harrington Road, Chetpet,
Chennai - 600 031, India.

Telephone : +91 44 4608 3100
Fax : +91 44 4608 3199

Limited review report on unaudited quarterly consolidated financial results and consolidated year to date financial results of Fortis Malar Hospitals Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To
Board of Directors of **Fortis Malar Hospitals Limited**

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of **Fortis Malar Hospitals Limited** ("the Parent") and its subsidiary Company (the Parent and its subsidiary together referred to as "the Group") for the quarter ended 30 September 2019 and year to date results for the period from 1 April 2019 to 30 September 2019 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). Attention is drawn to the fact that the consolidated figures for the corresponding quarter ended 30 September 2018 and corresponding period from 1 April 2018 to 30 September 2018, as reported in these financial results have been approved by the Parent's Board of Directors, but have not been subjected to review, since the requirement of submission of quarterly consolidated financial results has become mandatory only from 1 April 2019.
2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of Fortis Malar Hospitals Limited and its subsidiary Company- Malar Stars Medicare Limited.

102

B S R & Co. LLP


Limited review report on unaudited quarterly consolidated financial results and consolidated year to date financial results of Fortis Malar Hospitals Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

for B S R & Co. LLP

Chartered Accountants

Firm's Registration No. 101248W/W-100022



Amar Sunder

Partner

Membership No. 078305

UDIN: 19078305AAAAF05048

Place: Chennai

Date: 30 October 2019

BSR & Co. LLP

Chartered Accountants

KRM Tower, 1st & 2nd Floor,
No 1, Harrington Road, Chetpet,
Chennai - 600 031, India.

Telephone : +91 44 4608 3100
Fax : +91 44 4608 3199

Limited review report on unaudited quarterly standalone financial results and standalone year to date financial results of Fortis Malar Hospitals Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To
Board of Directors of **Fortis Malar Hospitals Limited**

1. We have reviewed the accompanying Statement of unaudited standalone financial results of Fortis Malar Hospitals Limited for the quarter ended 30 September 2019 and year to date results for the period from 1 April 2019 to 30 September 2019 ("the Statement"), being submitted by the Company pursuant to the requirements of Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ("Listing Regulations").
2. This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

r


Limited review report on unaudited quarterly standalone financial results and year to date financial results of Fortis Malar Hospitals Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

5. The figures for the quarter ended 30 September 2018 and year to date ended 30 September 2018 included in these financial results were reviewed by the predecessor auditor who expressed an unmodified opinion vide their limited review report 9 November 2018. Our conclusion on the statement is not modified in respect of above matter.

for B S R & Co. LLP

Chartered Accountants

Firm's Registration No. 101248W/W-100022



Amar Sunder

Partner

Membership No. 078305

UDIN: 19078305AAAAFN9589

Place: Chennai

Date: 30 October 2019

FORTIS MALAR HOSPITALS LIMITED (CIN: L85110PB1989PLC045948)

Regd. Office: Fortis Hospital, Sector 62, Phase – VIII, Mohali-160062

Tel Numbers: 0172 5096001 & Tele Fax No : 0172 5096002

Website: www.fortismalar.com; Email: secretarial.malar@malarhospitals.in

STATEMENT OF UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS PERIOD ENDED 30-SEPTEMBER-2019

2. STANDALONE AND CONSOLIDATED STATEMENT OF CASH FLOWS

Pursuant to the requirement in SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in relation to submission of statement of cash flows for the half year period with effect from 1 April 2019, the statement of cash flows for the half year ended 30 September 2019 has been presented in the table below. Considering that this is the first year of applicability of the aforesaid amendment, the comparative information has been provided for the previous year ended 31 March 2019.

| Particulars | Standalone | | Consolidated | |
|---|--------------------------------------|-----------------------------|--------------------------------------|-----------------------------|
| | Half year ended 30 September 2019 | Year ended 31 March 2019 | Half year ended 30 September 2019 | Year ended 31 March 2019 |
| | (Unaudited) | (Audited) | (Unaudited) | (Audited) |
| Cash flows from operating activities | | | | |
| Profit before tax for the period/ year | (632.65) | 235.99 | (611.45) | 279.07 |
| <i>Adjustments for:</i> | | | | |
| Interest income recognised in profit or loss | (355.45) | (853.83) | (364.75) | (896.47) |
| Loss on sale of assets | 0.49 | 7.64 | 0.49 | 7.64 |
| Depreciation and amortisation | 607.42 | 438.31 | 607.42 | 438.31 |
| Interest expense on lease liability | 376.95 | | 376.95 | |
| Allowance for credit losses | 33.87 | 1.99 | 33.87 | 1.99 |
| Advances written off | | 16.22 | | 16.22 |
| Liabilities no longer required written back | (85.35) | (114.61) | (85.35) | (114.61) |
| | (54.72) | (268.29) | (42.82) | (267.85) |
| <i>Movements in working capital:</i> | | | | |
| (Increase)/decrease in other current and non current financial assets | 193.36 | (550.47) | 181.55 | (537.26) |
| (Increase)/decrease in other current and non-current assets | (75.07) | (24.66) | (75.07) | (24.66) |
| (Increase)/decrease in trade and other receivables | 75.74 | (367.85) | 75.74 | (367.85) |
| (Increase)/decrease in inventories | 15.92 | 37.43 | 15.92 | 37.43 |
| (Increase)/decrease in provisions | 11.43 | 37.16 | 11.54 | 38.53 |
| Increase/ (decrease) in trade payables | (190.02) | (165.96) | (200.97) | (160.50) |
| Increase/ (decrease) in financial liabilities | - | (154.93) | - | (146.70) |
| Increase/ (decrease) in other current liabilities | 55.00 | 337.84 | 25.03 | 352.48 |
| Cash (used in) / generated from operations | 31.64 | (1,119.73) | (9.08) | (1,076.38) |
| Income taxes paid (net) | (210.12) | (453.12) | (165.60) | (520.40) |
| Net cash (used in) / generated by operating activities | (178.48) | (1,572.85) | (174.68) | (1,596.78) |
| Cash flows from investing activities | | | | |
| Payments to acquire fixed assets | (90.12) | (270.59) | (90.12) | (270.59) |
| Proceeds on sale of fixed assets | 0.19 | 0.34 | 0.19 | 0.34 |
| Interest received | 574.03 | 476.95 | 601.09 | 500.46 |
| Inter corporate deposits repaid by related parties | 4,087.54 | 547.46 | 4,207.54 | 547.45 |
| Fixed deposits not considered as cash and cash equivalents | (3,759.92) | (143.64) | (3,909.92) | (143.64) |
| Net cash generated / (used in) by investing activities | 811.72 | 610.52 | 808.78 | 634.02 |
| Cash flows from financing activities | | | | |
| Repayment of Lease Liabilities / Clinical establishment fees | (577.59) | - | (577.59) | - |
| Proceeds from issue of equity instruments of the Company | - | 15.07 | - | 15.07 |
| Net cash (used in)/ generated from financing activities | (577.59) | 15.07 | (577.59) | 15.07 |
| Net increase / (decrease) in cash and cash equivalents | 55.65 | (947.26) | 56.51 | (947.69) |
| Cash and cash equivalents at the beginning of the year | 503.52 | 1,450.78 | 503.67 | 1,451.36 |
| Cash and cash equivalents at the end of the year | 559.17 | 503.52 | 560.18 | 503.67 |



FORFIS MALAR HOSPITALS LIMITED (CIN: LK610PFI1989FLCM4948)
Reg. Office: Forfis Hospital, Sector 62, Phase - VIII, Mohali-160062
Forfis Hospital, Sector 62, Phase - VIII, Mohali-160062
Website: www.forfismalar.com Email: secretariat.malar@forfismalar.com

STATEMENT OF UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS PERIOD ENDED 30-SEPTEMBER-2019

Notes:

- 3 The unaudited standalone and consolidated financial results for the quarter ended 30 September 2019 and year to date ended 30 September 2019 have been reviewed by the Audit and Risk Management Committee and subsequently approved by the Board of Directors at their respective meeting held on 30 October 2019. The above results have not been reviewed by the statutory auditors of the Company. The auditors have issued an unmodified review report. Further, the consolidated financial result for the corresponding quarter ended 30 September 2018 and year to date ended 30 September 2018, as reported in these financial results have been approved by Audit and Risk Management Committee and subsequently approved by the Board of Directors at their respective meeting held on 30 October 2019, but have not been subjected to limited review by the Statutory auditors of the Company.
- 4 These unaudited financial results have been prepared in accordance with Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the Securities and Exchange Board of India (Listing, Obligations and Disclosure Requirements) Regulations, 2015.
- 5 The consolidated financial results includes the financial results of the Company Forfis Malar Hospitals Limited and the financial results of its subsidiary company Malar Sara Medicare Limited (collectively known as "Group")
- 6 The Company is engaged in the Healthcare Services, which in the context of Indian Accounting Standard (Ind AS) 108 - Operating Segments is considered as the only reportable segment of the Company.
- 7 Effective 1 April 2019, the Company has adopted Ind AS 116 - Leases, with the date of initial application being 1 April 2019, using the modified retrospective approach. Accordingly, the Company has recognized a lease liability at the date of initial application, at the present value of the remaining lease payments discounted using the incremental borrowing rate at the date of initial application, recognized right-of-use asset at the date of initial application equals to the lease liability recognized and the comparatives have not been retrospectively adjusted. In the profit and loss for the current period, the lease rent which was hitherto accounted under clinical establishment expenses/other expenses in the previous periods has now been accounted as depreciation charge for the right-of-use asset and finance cost for interest accrued on lease liability. Accordingly, the profit for the current quarter and six months period ended 30 September 2019 is lower by Rs. 73.8 lakhs and 150.70 lakhs (net of deferred tax created) respectively.
- 8 The Company had in earlier years applied to the Chennai Metropolitan Development Authority (CMDA) for regularization of certain deviations in the construction of the Hospital. During the year ended March 31, 2016, CMDA has issued an Order stating that the regularization application made by the Company has not been allowed. The Company had preferred an appeal before the Secretary to the Government of Tamil Nadu, Housing and Urban Development Authority against the said Order. On May 3, 2016 CMDA has also issued a Locking & Sealing and De-occupation Notice to the Company stating that in view of CMDA's Order dated March 18, 2016 referred above, the construction at the site of the Hospital premises is unauthorized and has called upon the Company to remove the land to its original condition within 30 days from the date of the Notice. The Company appealed to the High Court of Madras and obtained a stay order on June 02, 2016 directing CMDA not to proceed further, till the matter is disposed. As directed by the Hon'ble High Court of Madras, the Company has engaged an independent agency to conduct a safety audit of the Hospital premises and directed the Company to provide ramp facility for easy evacuation of patients. The Company has ramped up its fire detection and safety measures, constructed horizontal walkways and also obtained a Certificate from an independent agency on the safety of the Hospital premises. The Company, based on legal advice, believes that the above Order / Notices issued by CMDA are contestable and the same prima facie would not result in adverse impact on it's operations/ going concern as the Company has fair chance of success in the aforesaid Appeal / writ petition.
- 9 Figures for the prior periods / year have been reclassified/ regrouped wherever required to conform to the classification of the current period.
- 10 These financial results are available on the BSE website (www.bseindia.com) and on the Company's website (www.forfismalar.com).



Place: Chennai
Date: 30 October 2019

By Order of the Board

For and on behalf of Board of Directors of Forfis Malar Hospitals Limited


Daji Singh
Chairman
DIN No. 00135414



FORTIS MALAY HOSPITALS LIMITED (CIN: L8510FB198PFLCM45848)
 Regd. Office: Fortis Hospitals, 6th Phase - VIII, Mohali-160062.
 Tel Numbers: 0172 5996001 & 0172 5996002.
 Website: www.fortismal.com; Email: secretariat@fortismal.com

STATEMENT OF UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS PERIOD ENDED 30-SEPTEMBER-2019

| No. Particulars | Standalone Quarter ended | | Standalone Half Year ended | | Standalone Year ended | | Consolidated Quarter ended | | Consolidated Half Year ended | | Consolidated Year ended | |
|--|----------------------------|----------------------------|----------------------------|----------------------------|--------------------------|----------------------------|----------------------------|----------------------------|------------------------------|----------------------------|----------------------------|--------------------------|
| | 30-Sep-2019 (Unaudited) | 30-Jun-2019 (Unaudited) | 30-Sep-2019 (Unaudited) | 30-Jun-2019 (Unaudited) | 31-Mar-2019 (Audited) | 30-Sep-2019 (Unaudited) | 30-Jun-2019 (Unaudited) | 30-Sep-2019 (Unaudited) | 30-Jun-2019 (Unaudited) | 30-Sep-2019 (Unaudited) | 30-Jun-2019 (Unaudited) | 31-Mar-2019 (Audited) |
| 1 Income | | | | | | | | | | | | |
| a) Revenue from operations | 3,070.42 | 3,187.38 | 7,070.89 | 7,070.89 | 14,459.39 | 3,070.42 | 3,187.38 | 3,714.76 | 3,714.76 | 6,257.80 | 7,070.89 | 14,459.39 |
| b) Other income | 189.23 | 251.57 | 440.80 | 434.09 | 968.44 | 201.97 | 260.87 | 225.66 | 225.66 | 462.84 | 453.47 | 1,011.08 |
| Total income | 3,259.65 | 3,438.95 | 6,698.60 | 7,504.98 | 15,427.83 | 3,272.39 | 3,448.25 | 3,940.42 | 3,940.42 | 6,720.64 | 7,526.36 | 15,470.47 |
| 2 Expenses | | | | | | | | | | | | |
| a) Purchase of medical consumables and drugs | 736.59 | 661.09 | 1,397.68 | 1,614.87 | 3,002.36 | 736.59 | 661.09 | 850.44 | 850.44 | 1,397.68 | 1,614.87 | 3,302.36 |
| b) Changes in inventories of medical consumables and drugs | 1.64 | 14.28 | 15.92 | 40.48 | 37.43 | 1.64 | 14.28 | 36.91 | 36.91 | 15.92 | 40.48 | 37.43 |
| c) Employee benefits expense | 585.46 | 553.36 | 1,138.82 | 1,157.79 | 2,314.50 | 588.16 | 556.06 | 593.61 | 593.61 | 1,144.22 | 1,172.89 | 2,345.85 |
| d) Finance costs | 198.06 | 196.84 | 394.90 | 393.83 | 50.90 | 198.06 | 196.84 | 16.25 | 16.25 | 394.90 | 29.83 | 50.90 |
| e) Professional charges / consultation fees to doctors | 991.75 | 994.15 | 1,985.73 | 2,052.57 | 4,016.39 | 988.65 | 991.04 | 1,057.19 | 1,057.19 | 1,979.69 | 2,035.87 | 3,983.18 |
| f) Clinical establishment fees | 226.06 | 238.54 | 464.60 | 1,049.79 | 2,114.99 | 226.06 | 238.54 | 538.93 | 538.93 | 464.60 | 1,049.79 | 2,114.99 |
| g) Depreciation and amortization expenses | 305.21 | 302.22 | 607.42 | 215.58 | 438.31 | 305.21 | 302.22 | 108.17 | 108.17 | 607.42 | 215.58 | 438.31 |
| h) Other expenses | 662.63 | 663.38 | 1,326.01 | 1,398.83 | 2,910.96 | 663.59 | 664.07 | 683.22 | 683.22 | 1,327.66 | 1,399.23 | 2,918.38 |
| Total expenses | 3,707.40 | 3,623.86 | 7,331.25 | 7,559.84 | 15,191.84 | 3,707.36 | 3,624.14 | 3,884.72 | 3,884.72 | 7,332.09 | 7,558.54 | 15,191.40 |
| 3 Profit / (loss) from ordinary activities before tax (1-2) | (447.75) | (184.91) | (632.65) | (1054.86) | (235.99) | (435.50) | (175.89) | (55.70) | (55.70) | (611.45) | (321.88) | (279.07) |
| 4 Tax expense | (124.56) | (51.44) | (176.00) | (22.51) | 62.32 | (121.56) | (48.93) | 9.89 | 9.89 | (170.49) | (16.62) | 73.52 |
| 5 Net profit / (loss) from ordinary activities after tax (3-4) | (322.19) | (133.47) | (458.65) | (127.35) | 173.67 | (314.00) | (126.96) | 45.81 | 45.81 | (440.96) | (15.56) | 205.55 |
| Other comprehensive income / (loss) (net of tax) Items that will not be reclassified subsequently to the statement of profit and loss: | | | | | | | | | | | | |
| (a) Remeasurements of the defined benefit plans | 43.16 | (15.74) | 27.42 | 25.23 | 15.41 | 43.16 | (15.74) | 11.41 | 11.41 | 27.42 | 25.23 | 17.03 |
| (b) Income tax relating to items that will not be reclassified to profit or loss | (12.01) | 4.38 | (7.63) | (7.02) | (4.29) | (12.01) | 4.38 | (5.58) | (5.58) | (7.63) | (7.02) | (4.71) |
| 6 Other comprehensive income/ (loss) for the period (5+6) | 31.15 | (11.36) | 19.79 | 18.21 | 11.12 | 31.15 | (11.36) | 5.83 | 5.83 | 19.79 | 18.21 | 12.32 |
| Total comprehensive income/ (loss) attributable to: | (292.04) | (144.83) | (438.86) | (109.14) | 184.79 | (282.85) | (138.32) | 51.64 | 51.64 | (421.17) | 2.65 | 217.87 |
| - Owners of the company | NA | NA | NA | NA | NA | (282.85) | (138.32) | 51.64 | 51.64 | (421.17) | 2.65 | 217.87 |
| - Non-controlling interests | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| 8 Paid up equity share capital (face value Rs.10 each) | 1,875.70 | 1,875.70 | 1,875.70 | 1,875.70 | 1,875.70 | 1,875.70 | 1,875.70 | 1,875.70 | 1,875.70 | 1,875.70 | 1,875.70 | 1,875.70 |
| 9 Reserves excluding evaluation reserves | NA | NA | NA | NA | 8,483.73 | NA | NA | NA | NA | NA | NA | 8,661.91 |
| 10 Earnings Per Share (EPS) based on (f) above (of Rs. 10 each) - (Not annualised in the quarters) | | | | | | | | | | | | |
| - Basic | (1.73) | (0.71) | (2.44) | (0.17) | 0.93 | (1.67) | (0.68) | 0.24 | 0.24 | (2.35) | (0.08) | 1.10 |
| - Diluted | (1.73) | (0.71) | (2.44) | (0.17) | 0.92 | (1.67) | (0.68) | 0.24 | 0.24 | (2.35) | (0.08) | 1.09 |



FORTIS MALAR HOSPITALS LIMITED (CIN: L85110PB1989PLC045948)
 Regd. Office: Fortis Hospital, Sector 62, Phase - VIII, Mohali-160062
 Tel Numbers: 0172 5096001 & Tele Fax No : 0172 5096002
 Website: www.fortismalar.com; Email: secretarial.malar@malarhospitals.in


STATEMENT OF UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS PERIOD ENDED 30-SEPTEMBER-2019

Notes:

I. STANDALONE AND CONSOLIDATED STATEMENT OF ASSETS AND LIABILITIES

(Rs. in lakhs)

| Particulars | Standalone | | Consolidated | |
|---|-----------------------------------|-----------------------------|-----------------------------------|-----------------------------|
| | As at | As at | As at | As at |
| | September 30, 2019 (Unaudited) | March 31, 2019 (Audited) | September 30, 2019 (Unaudited) | March 31, 2019 (Audited) |
| ASSETS | | | | |
| Non-current assets | | | | |
| (a) Property, plant and equipment | 1,944.68 | 2,062.26 | 1,944.68 | 2,062.26 |
| (b) Capital Work-in-Progress | 8.00 | - | 8.00 | - |
| (c) Right of use Assets | 6,437.92 | - | 6,437.92 | - |
| (d) Intangible assets under development | 72.97 | 72.97 | 72.97 | 72.97 |
| (e) Other intangible assets | 111.68 | 122.43 | 111.68 | 122.43 |
| (f) Financial assets | 5.00 | 5.00 | - | - |
| (i) Investment in subsidiary | 91.32 | 78.72 | 91.32 | 78.72 |
| (ii) Other financial assets | 353.49 | 185.12 | 354.99 | 186.59 |
| (g) Deferred tax assets (net) | 1,424.83 | 1,207.08 | 1,487.65 | 1,319.96 |
| (h) Income tax assets | 23.10 | 29.92 | 23.10 | 29.92 |
| (i) Other non-current assets | - | - | - | - |
| Total non-current assets | 10,472.99 | 3,763.50 | 10,532.31 | 3,872.85 |
| Current assets | | | | |
| (a) Inventories | 148.89 | 164.81 | 148.89 | 164.81 |
| (b) Financial assets | | | | |
| (i) Trade receivables | 856.61 | 966.22 | 856.61 | 966.22 |
| (ii) Cash and cash equivalents | 559.17 | 503.52 | 560.18 | 503.67 |
| (iii) Bank balances other than (ii) above | 3,920.70 | 160.78 | 4,070.70 | 160.78 |
| (iv) Loans | 3,500.00 | 7,587.54 | 3,500.00 | 7,707.54 |
| (v) Other financial assets | 1,134.71 | 1,561.73 | 1,134.68 | 1,567.66 |
| (c) Other current assets | 224.68 | 141.66 | 224.68 | 141.66 |
| Total current assets | 10,344.76 | 11,086.26 | 10,495.74 | 11,212.34 |
| Total assets | 20,817.75 | 14,849.76 | 21,028.05 | 15,085.19 |
| EQUITY AND LIABILITIES | | | | |
| Equity | | | | |
| (a) Equity share capital | 1,875.70 | 1,875.70 | 1,875.70 | 1,875.70 |
| (b) Other equity | 8,046.87 | 8,483.73 | 8,240.75 | 8,661.91 |
| Total equity | 9,922.57 | 10,359.43 | 10,116.45 | 10,537.61 |
| Liabilities | | | | |
| Non-current liabilities | | | | |
| (a) Financial liabilities | | | | |
| (i) Lease liability | 6,192.40 | - | 6,192.40 | - |
| (ii) Other financial liabilities | 150.91 | 155.34 | 156.69 | 160.72 |
| (b) Provisions | 6,343.31 | 155.34 | 6,349.09 | 160.72 |
| Total non-current liabilities | | | | |
| Current liabilities | | | | |
| (a) Financial liabilities | | | | |
| (i) Lease liability | 454.79 | - | 454.79 | - |
| (ii) Trade payables | 2,141.13 | 2,331.15 | 2,151.77 | 2,352.74 |
| (iii) Other financial liabilities | 567.79 | 581.41 | 567.79 | 581.41 |
| (b) Provisions | 108.61 | 112.53 | 108.61 | 112.83 |
| (c) Current tax liabilities (Net) | 5.71 | 5.71 | 5.71 | 5.71 |
| (d) Other current liabilities | 1,273.84 | 1,304.19 | 1,273.84 | 1,334.17 |
| Total current liabilities | 4,551.87 | 4,334.99 | 4,562.51 | 4,386.86 |
| Total liabilities | 10,895.18 | 4,490.33 | 10,911.60 | 4,547.58 |
| Total equity and liabilities | 20,817.75 | 14,849.76 | 21,028.05 | 15,085.19 |



**FORTIS MALAR REPORTS Q2 FY20 CONSOLIDATED REVENUE AT RS 30.70 CR
OPERATING PROFIT FOR THE QUARTER AT (-) RS.1.34 CR**

Chennai, October 30, 2019: Fortis Malar Hospitals Limited, a subsidiary of Fortis Healthcare Limited, a leading integrated healthcare delivery provider in India, today announced its results for the quarter ended September 30, 2019.

Commenting on the results, Mr. Daljit Singh, Chairman, Fortis Malar Hospitals Limited, said, “Fortis Malar has been doing exceptional clinical work and has achieved the unique distinction of conducting over 325 Thoracic organ transplants, reinforcing its position as a world-class super speciality tertiary care centre. Additionally, it has made a mark for itself by performing complex and high-end surgeries particularly in Cardiology, Neurology and Mother & Child Care, among others. I am delighted with the great work being done by our team of doctors, nurses, paramedics and other staff members and I am confident that we will continue to deliver world-class clinical programmes, with consistently superior results in the future, as well.”

Financial Highlights (consolidated) for the Quarter (Q2FY20)

- Fortis Malar Hospitals reported operating revenue of Rs 30.70 Cr compared to Rs 37.15 Cr reported in the corresponding quarter of the previous year.
- Operating profit / (loss) for the quarter stood at Rs (-) 1.34 Cr compared to Rs (-) 0.46 Cr in the corresponding quarter of previous year.
- Profit before tax stood at Rs. (-) 4.36 Cr compared to Rs. 0.56 Cr in corresponding quarter of previous year.
- Net profit for the quarter was at Rs (-) 3.14 Cr compared to Rs.0.46 Cr in corresponding quarter of previous year.
- Revenue from Neuro Science and Cardiothoracic grew by 10% and 2% respectively compared to the corresponding quarter of previous year.

Financial Highlights – H1FY19

- Operating revenue for H1FY20 at Rs 62.58 Cr compared to Rs 70.71 Cr reported in the corresponding previous period.
- Operating profit for H1FY20 stood at Rs (-) 0.72 Cr compared to Rs (-) 2.42 Cr in the corresponding previous period.
- Profit before tax stood at Rs. (-) 6.11 Cr compared to Rs. (-) 0.32 Cr in previous year period.
- Net profit for H1FY20 was at Rs (-) 4.41 Cr compared to Rs. (-) 0.16 Cr in corresponding previous period

Operational Highlights for the Q2FY20

- **93-year-old man with hip fracture walks on the same day after a complex hip procedure**
A team of doctors at Fortis Malar Hospital led by Dr. Nandkumar Sundaram, Senior Consultant, Trauma & Orthopaedic Surgeon, Fortis Malar Hospital successfully performed a minimally invasive Proximal Femoral Nail (PFN) procedure on 93-year-old Mr. Aravamudhan who walked on the same day, 6 hours after the procedure.
- **Fortis Malar conducts an impactful session on mental fitness for college students**
On the occasion of World Suicide Prevention Day, Fortis Malar Hospital conducted an enlightening session for students of Kumararani Meena Muthiah College of Arts And Science. The two-hour session was led by Ms. Sneha George, Counselling Psychologist, Fortis Malar Hospital focussing on understanding of suicide and how to start critical conversations.
- **Fortis Malar Hospital organises 'Know Your Heart' session this World Heart Day**
On the occasion of World Heart Day, Fortis Malar Hospital conducted an awareness session 'Know Your Heart' led by Dr. Pradeep Nayar, Senior Consultant Cardiology, Fortis Malar Hospital. The session conducted at Thiruvalluvar Nagar, Thiruvannamiyur Beach emphasized the significance of physical activity for maintaining a healthy heart. A gathering of over 50 enthusiastic middle - aged people from East Coast Beach Walker's Association participated in the event. An exclusive Tai Chi activity was also conducted by Mr. M Dhanasekaran, Karate World Champion 2013- Japan, Sub Inspector of Police (Retired) who introduced the participants to this gentle form of exercise involving various flexible postures and seamless body movements for improved heart function.
- **Fortis Malar Hospital successfully performs 3 organ transplants in 13 hours**
Fortis Malar hospital successfully performed three organ transplants within a time frame of 13 hours. This feat was achieved by the team of doctors led by Dr. K R Balakrishnan, Director, Cardiac Sciences, Fortis Malar Hospital and Dr. Suresh Rao KG, Head of Department, Critical Care & Cardiac Anaesthesia, Fortis Malar Hospital. A 61-year-old man from Rajasthan who was suffering Ischemic Cardiomyopathy and a 13-year-old girl from Chennai who was diagnosed with primary pulmonary hypertension underwent heart and bilateral lung transplant respectively. The 28-year-old female from Guntur with dilated cardiomyopathy underwent a heart transplant.
- **To mark World Breastfeeding Week, Fortis Malar Hospital organizes an interactive expert based session on breastfeeding**
On the occasion of World Breastfeeding Week, Fortis Malar Hospital conducted a unique session dedicated to breastfeeding and lactation at The Raintree, Anna Salai. The session comprised of audience consisting of new and expectant mothers along with their husbands and parents. Experts in this field, Dr Jayashree Jayakrishnan, Lactation Consultant, Fortis Malar and Dr Premalatha, Consultant - Gynaecology, Fortis Malar Hospital addressed crucial topics like challenges in breastfeeding, cost of inadequate breastfeeding and the need for reinforcement of breastfeeding.
- **Fortis Malar encourages school students to choose medical profession as a career option**
Fortis Malar Hospital organized a unique activity by reaching out to 50 students of Biological Sciences belonging to class XI and XII of Avvai Girls Higher Secondary School, Besant Nagar. In order to gain insights as well as have more clarity on the roles, significances, challenges and responsibilities of the doctors, each doctor was assigned a set of students which allowed them to interact and learn the basics with regard to the daily duties and responsibilities followed by doctors. Apart from donning the medical coat along with stethoscopes, the students also received firsthand experience of a day in the life of a doctor.

- **Mums-to-be try aquanatal along with their partners**
Fortis Malar Hospital in association with Happymom conducted Aquanatal classes for pregnant couples in their second/ third trimester. The session focussed on positions, breathing and comfort techniques. Aquanatal classes are exercises carried out in water which are specifically devised for pregnant women. These exercises help the mother to feel good about themselves and is a fun and safe way to keep active during pregnancy. The physical benefits of exercise helps pregnant women cope with the extra strain placed on their bodies.
- **Arunachal Pradesh's first ever successful Heart and Lung transplant performed by Fortis Malar team**
A team of senior doctors from Fortis Malar Hospital successfully conducted a heart and lung transplant on 23-year-old woman from Roing in Arunachal Pradesh. The patient, named Mumni Tayeng, was diagnosed with Eisenmenger's syndrome. She is the first person from Arunachal Pradesh to receive heart and lung transplant. This clinical feat was achieved by an enterprising team of expert doctors led by Dr K R Balakrishnan, Director, Cardiac Sciences and Dr Suresh Rao KG, Head of Department, Critical Care & Cardiac Anaesthesia, Fortis Malar Hospital.
- **Doctors at Fortis Malar Hospital successfully implants World's Smallest Heartware Ventricular Device (HVAD) pump to save Pakistani Girl with Heart Failure**
Doctors at Fortis Malar Hospital successfully implanted world's smallest pump - Heartware Ventricular Device (HVAD) on a 14-year girl from Pakistan. This challenging and complex procedure was conducted by a team of expert doctors led by by Dr. K R Balakrishnan, Director, Cardiac Sciences, Fortis Malar Hospital and Dr. Suresh Rao KG, Head of Department, Critical Care & Cardiac Anaesthesia, Fortis Malar Hospital.
- **Fortis Malar conducts a multi-specialty screening camp for employees of Greater Chennai Corporation at Ripon Building**
Fortis Malar Hospital today organized a multi-specialty screening camp for over 200 employees of Greater Chennai Corporation at the Ripon Building which included manual scavengers, members from the Department of Solid Waste Management, conservancy workers and workers in-charge of cleaning and sweeping. The camp screened the participants for Hepatitis, Blood Pressure, Random Blood Sugar levels and body mass index. Ortho and cardiac tests were also conducted as a part of the screening process.
- **Fortis Malar Hospital successfully performs a one of its kind minimally invasive cardiac surgery**
Fortis Malar Hospital recently performed a minimally invasive Transcatheter Aortic Valve Replacement (TAVR) valve-in-valve procedure on a 65 year old man with a dysfunctional bioprosthetic aortic valve. This rare procedure was conducted by a team of expert doctors led by Dr E Babu, Consultant Heart Failure & Interventional Cardiologist at Fortis Malar Hospital, Adyar, Chennai.

About Fortis Malar Hospitals Ltd

Fortis Malar Hospital (formerly known as Malar Hospital) was acquired by Fortis Healthcare (India) Limited in early 2008. The hospital founded in 1992, is established as one of the largest corporate hospitals in Chennai providing quality super specialty and multi-specialty healthcare services. Fortis Malar Hospitals, with 180 beds, focuses on providing comprehensive medical care in the areas of Cardiology and Cardiac Surgery, Neuro Surgery, Gynecology, Orthopedics, Gastroenterology, Neurology, Pediatrics, Diabetics, Nephrology and Internal Medicine.

Fortis Malar Hospital has a state of the art Cath Lab and multiple dedicated cardiac operation theatres and intensive coronary care units. Several rare and complex Adult and Paediatric Cardiac surgeries, Orthopedic and Joint replacements, Neurosurgeries and Plastic reconstruction surgeries have been performed at this hospital. The

Press Release



hospital's Obstetrics and Gynaecology services are among the busiest in the city, successfully performing many complicated deliveries and surgeries. They are supported by a dedicated Neonatology unit.

About Fortis Healthcare Ltd

Fortis Healthcare Limited is a leading integrated healthcare delivery service provider in India. The healthcare verticals of the company primarily comprise hospitals, diagnostics and day care specialty facilities. Currently, the company operates its healthcare delivery services in India, Dubai and Sri Lanka with 36 healthcare facilities (including projects under development), approximately 9000 potential beds and over 410 diagnostic centers.

DISCLAIMER

This press release may contain forward-looking statements based on the currently held beliefs and assumptions of the management of the Company, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance, or achievements of the Company results, to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements. Given these risks, uncertainties and other factors, recipients of this press release are cautioned not to place undue reliance on these forward-looking statements. The Company assumes no responsibility to publicly amend, modify or revise any forward looking statements, on the basis of any subsequent development, information or events, or otherwise. The information contained herein is subject to change without notice and past performance is not indicative of future results. The Company may alter, modify or otherwise change in any manner the content of this press release, without obligation to notify any person of such revision or changes.

FOR MORE INFORMATION PLEASE CONTACT

Rokesh A
PR & Communications
Fortis Malar Hospitals Ltd
Mobile:8667867754
rokesh.a@fortishealthcare.com

A handwritten signature in blue ink, consisting of a stylized, cursive name that appears to be "Rokesh A".